NIH, Hubei trials of remdesivir could be more telling than Gilead’s
A look at the five Phase II and III clinical trials testing remdesivir to treat COVID-19 suggests the Gilead-sponsored trials may be less informative about efficacy.
Three different organizations are sponsoring the studies. NIH’s adaptive Phase II trial and the two Phase III trials being run by China-Japan Friendship Hospital are blinded trials with placebo control arms; whereas the two Phase III studies that Gilead Sciences Inc. (NASDAQ:GILD) announced Wednesday are both open-label. One of the Gilead trials has no control arm, while the other has a non-blinded standard-of-care arm (see “COVID-19 Roundup”).
Remdesivir is an investigational agent that Gilead was already developing for Ebola when the COVID-19 outbreak occurred. The WHO’s R&D Blueprint Clinical Trials expert group named the nucleotide analog the most promising candidate for COVID-19 in a Jan. 29 draft report (see “WHO Prioritizing Gilead’s Remdesivir”).